MLAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mesa Laboratories Inc (MLAB) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown some positive revenue growth and margin expansion, the significant drop in net income and EPS, coupled with neutral trading sentiment and lack of recent positive catalysts, suggests that waiting for clearer signals or stronger performance metrics would be prudent. The technical indicators are neutral, and no strong trading signals are present to justify immediate action.
The MACD is positive and expanding, indicating a mild bullish trend. RSI is neutral at 48.293, suggesting no overbought or oversold conditions. Moving averages are converging, and the stock is trading near its resistance level of R1: 83.823. Overall, the technical indicators do not provide a strong buy signal.
Wells Fargo raised the price target from $83 to $94, citing strong Q3 revenue and adjusted EBITDA performance, along with margin expansion. Management's shareholder-friendly steps and reduced leverage are also noted as positives.
Additionally, there is no recent news or significant trading activity from insiders, hedge funds, or Congress to support a bullish sentiment. Stock trend analysis indicates a potential short-term decline.
In Q3 2026, revenue increased by 3.64% YoY to $65.13M, and gross margin improved slightly to 64.18%. However, net income dropped drastically to $3.63M (-316.59% YoY), and EPS fell to 0.65 (-309.68% YoY). This indicates declining profitability despite revenue growth.
Wells Fargo maintains an Equal Weight rating but raised the price target to $94 from $83, citing strong Q3 performance and improved financial metrics. However, the Equal Weight rating suggests a neutral stance overall.
